Nuvation Bio Inc.
NYSE:NUVB
Overview | Financials
Company Name | Nuvation Bio Inc. |
Symbol | NUVB |
Currency | USD |
Price | 2.68 |
Market Cap | 901,999,560 |
Dividend Yield | 0% |
52-week-range | 1.43 - 4.16 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. David T. Hung M.D. |
Website | https://www.nuvationbio.com |
An error occurred while fetching data.
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD